Update information

June 2026: We reviewed the evidence and made new and updated recommendations and recommendations for research on providing information and supportive care, diagnosis and assessment, and systemic anticancer therapy. These recommendations are marked [2026], [2017, amended 2026] and [2009, amended 2026]. We also added links to relevant technology appraisal guidance in the sections on diagnosis and assessment and systemic anticancer therapy. Some recommendations have been stood down as they no longer reflect current practice.

February 2025: Recommendations in the section on lymphoedema have been stood down as they have been superseded by the update on lymphoedema early identification, risk reduction and management in the NICE guideline on early and locally advanced breast cancer: diagnosis and management.

August 2017: We reviewed the evidence and updated recommendations in section 1.1 on assessing oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status on disease recurrence. These recommendations are marked [2017].

ISBN: 978-1-4731-9587-5